BioSpace News Archive

180 Life Sciences Corp. announced the closing of its previously announced private placement of 2,500,000 shares of its common stock and accompanying warrants to purchase an aggregate of up to 2,500,000 shares of common stock at a combined purchase price of $6.00 per share and accompanying warrant.

ID Genomics, a Seattle-based company, has invented a dipstick-based, rapid test for simultaneous identification of a large number of genetic variants of SARS-CoV-2 and has just received a National Institutes of Health grant to expedite bringing this test to market.

The McQuade Center for Strategic Research and Development, LLC announces that it has entered an agreement with Aché Laboratórios Farmacêuticos S.A., a leader in the Latin American pharmaceutical market, to co-develop a therapy with the potential to treat general anxiety disorder and post-traumatic stress disorder.

Humanetics Corporation (Humanetics) announced today that BIO 300, a drug under development to increase survival in persons exposed to high levels of radiation, has been granted Fast Track status by the U.S. Food and Drug Administration (FDA).

Allergic Rhinitis is also referred as hay fever. Allergic rhinitis is caused because of several allergens such as pollens, mould, animal dander and dust.

Tonix Pharmaceuticals Holding Corp., a clinical-stage biopharmaceutical company, announced that it received the official minutes from a Type B pre-Investigational New Drug Application meeting with the U.S. Food and Drug Administration to develop TNX-102 SL1 as a potential treatment for Long COVID Syndrome, which is now known officially as Post-Acute Sequelae of COVID-19.

Atea Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, announced the publication of data demonstrating the in vitro and in vivo activity of AT-752 against dengue virus infection, in the journal, Antimicrobial Agents and Chemotherapy.

Vyriad, Inc., a clinical-stage biotechnology company developing oncolytic virus therapies to treat a wide range of cancers, announced the appointment of leading life sciences investor Harry Hoffman to the Company’s board of directors.

Encision Inc., a medical device company owning patented Active Electrode Monitoring Technology that prevents dangerous stray electrosurgical burns in minimally invasive surgery, announced that Encision has signed a Supply Agreement with Auris Health, Inc., part of the Johnson & Johnson Medical Devices Companies.

Umoja Biopharma, an oncology company leveraging its proprietary integrated technologies to reprogram immune cells in vivo to create next-generation immunotherapies for the treatment of solid tumors and hematologic malignancies, announced the appointment of Greg Sargen to its Board of Directors.